Evidence map›Paper›PMID 28645939›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.

Carsten U Niemann, Helena I Mora-Jensen, Eman L Dadashian, Fanny Krantz, Todd Covey, Shih-Shih Chen, Nicholas Chiorazzi, Raquel Izumi, Roger Ulrich, Brian J Lannutti and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Carsten U NiemannHematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.
Helena I Mora-JensenHematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.
Eman L DadashianHematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.
Fanny KrantzAcerta Pharma, Redwood City, California.
Todd CoveyAcerta Pharma, Redwood City, California.
Shih-Shih ChenThe Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York.
Nicholas ChiorazziThe Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York.
Raquel IzumiAcerta Pharma, Redwood City, California.
Roger UlrichAcerta Pharma, Redwood City, California.
Brian J LannuttiAcerta Pharma, Redwood City, California.
Adrian WiestnerHematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland. sarah.herman@nih.gov wiestnera@mail.nih.gov.
Sarah E M HermanHematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland. sarah.herman@nih.gov wiestnera@mail.nih.gov.
Rigshospitalet · DK

Funding

Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapyZIAHL002346 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI WIESTNER, ADRIAN U · 2009 to 2025
$29.8M
Intramural NIH HHS Z99 HL999999Intramural NIH HHS ZIA HL002346
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdenosineAgammaglobulinaemia Tyrosine KinaseAnimalsApoptosisBenzamidesB-LymphocytesCell Line, TumorCell ProliferationClass Ia Phosphatidylinositol 3-KinaseDisease Models, AnimalDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansLeukemia, Lymphocytic, Chronic, B-CellMiceNeoplasm ProteinsacalabrutinibAdenosineAgammaglobulinaemia Tyrosine KinaseBenzamidesBTK protein, humanBtk protein, mouseClass Ia Phosphatidylinositol 3-KinaseN-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amineNeoplasm ProteinsPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrazinesQuinolines

Identifiers

PMID28645939
PMCPMC5626587
OpenAlexW2665803427

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.